Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
The patient got so bad, had a cold, throat ache, running nose and cough and mucus and etc.; The patient got so bad, had a cold, throat ache, running nose and cough and mucus and etc.; The patient got so bad, had a cold, throat ache, running nose and cough and mucus and etc.; The patient got so bad, had a cold, throat ache, running nose and cough and mucus and etc.; Case reference number US-BN-2025-000947 is a spontaneous case initially received from a physician via Communications (reference number: USBAV25-1137) on 16-May-2025 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. The patient's current conditions included a sore throat and thought they were getting better. On an unspecified date, as reported on Wednesday, the patient took first dose of Vivotif (batch number: unknown), at unknown dose, orally for indication travel. On an unspecified date, unknown amount of time after first dose of Vivotif, as reported the patient got so bad had a cold now, throat ache, running nose and cough and mucus and etc. At the time of the initial report, it was unknown if the patient recovered from the events of 'cold', 'throat pain','rhinorrhoea' and 'cough'. The reporter assessed the events of 'cold', 'throat pain','rhinorrhoea' and 'cough' as non-serious. The reporter assessed the events of 'cold', 'throat pain','rhinorrhoea' and 'cough' as not related to Vivotif. No further information was provided.; Reporter's Comments: This case concerns a female patient of unspecified age, who took first dose of Vivotif vaccine on unspecified date for an indication travel. After unknown amount of time on unspecified date, patient developed non-serious events of nasopharyngitis, oropharyngeal pain, rhinorrhoea and cough. Nasopharyngitis, oropharyngeal pain, rhinorrhoea and cough are unlisted per CCDS V8 and unexpected per USPI. Patient's medical history and concomitant medications was not reported. Outcome was unknown. Based on the limited information provided regarding this case, the causal role of the suspect vaccine cannot be excluded in the occurrence of the events, hence the events are considered related to the suspect vaccine. This case is considered as non-serious.; Sender's Comments: This case concerns a female patient of unspecified age, who took first dose of Vivotif vaccine on unspecified date for an indication travel. After unknown amount of time on unspecified date, patient developed non-serious events of nasopharyngitis, oropharyngeal pain, rhinorrhoea and cough. Nasopharyngitis, oropharyngeal pain, rhinorrhoea and cough are unlisted per CCDS V8 and unexpected per USPI. Patient's medical history and concomitant medications was not reported. Outcome was unknown. Based on the limited information provided regarding this case, the causal role of the suspect vaccine cannot be excluded in the occurrence of the events, hence the events are considered related to the suspect vaccine. This case is considered as non-serious.
Sore throat